Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $31.19 -0.48 (-1.52%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sutro Biopharma Stock (NASDAQ:STRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$30.49▼$32.7250-Day Range$20.68▼$40.9152-Week Range$6.74▼$43.85Volume155,968 shsAverage Volume193,529 shsMarket Capitalization$516.82 millionP/E RatioN/ADividend YieldN/APrice Target$48.25Consensus RatingBuy Company Overview Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas. With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.AI Generated. May Contain Errors. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 365th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSutro Biopharma has a consensus price target of $48.25, representing about 52.4% upside from its current price of $31.67.Amount of Analyst CoverageSutro Biopharma has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($9.48) to ($8.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sutro Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.27% of the float of Sutro Biopharma has been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 3.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 30.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.24 News SentimentSutro Biopharma has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Sutro Biopharma this week, compared to 3 articles on an average week.Search Interest4 people have searched for STRO on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17 at 3:06 PM | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 20 at 1:00 AM | Behind the Markets (Ad)Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14, 2026 | globenewswire.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $11.57 at the beginning of the year. Since then, STRO shares have increased by 173.7% and is now trading at $31.67. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings results on Thursday, May, 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.74) by $0.20. The business had revenue of $14.52 million for the quarter, compared to analyst estimates of $8.89 million. When did Sutro Biopharma's stock split? Sutro Biopharma's stock reverse split on Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $85 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,667,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's top institutional investors include Affinity Asset Advisors LLC (6.45%), Orbimed Advisors LLC (4.83%), ADAR1 Capital Management LLC (3.17%) and Renaissance Technologies LLC (0.59%). Insiders that own company stock include Jane Chung, Hans-Peter Gerber, David Pauling, Connie Matsui, Gregory K Chow, Nicki Vasquez and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings5/14/2026Today5/20/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/27/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 STRO's financial health is in the Green zone, according to TradeSmith. STRO has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year Founded2003Price Target and Rating Average Price Target for Sutro Biopharma$48.25 High Price Target$100.00 Low Price Target$20.00 Potential Upside/Downside+55.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($11.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$191.09 million Net Margins-154.21% Pretax Margin-154.32% Return on EquityN/A Return on Assets-69.20% Debt Debt-to-Equity RatioN/A Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual Sales$99.61 million Price / Sales5.15 Cash FlowN/A Price / Cash FlowN/A Book Value($4.04) per share Price / Book-7.66Miscellaneous Outstanding Shares16,570,000Free Float15,592,000Market Cap$512.68 million OptionableOptionable Beta1.63 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:STRO) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersThe Last Time This Market Moved, Early Investors Took NoticeLithium has already had one major run - and now prices are starting to move again. EV adoption and energy stor...i2i Marketing Group, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayI spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...Decentralized Masters | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
